We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blood Levels of Ebola Virus Are Predictive of Death

By LabMedica International staff writers
Posted on 14 Dec 2015
Currently, most treatments used in Ebola treatment centers (ETCs) rely on supportive care, but several experimental therapies are being assessed for Ebolavirus disease (EVD) following promising in vitro and limited in vivo findings. More...


The relationship between patients’ viremia or viral load and their probability of death has been assessed and how this relationship may be used to explain temporal trends in reported case fatality rates (CFRs) and inform different treatment study designs has been investigated.

Scientists from the Institut Pasteur (Dakar, Senegal) and their international colleagues used laboratory, clinical, and demographic data for 699 patients with confirmed EVD hospitalized in the Conakry area of Guinea between March 2014 and February 2015 to model the association between viremia and CFR. A blood sample was collected from all suspected EVD patients, and a real-time reverse transcriptase polymerase chain reaction (RT-PCR) test was performed systematically. If the test is positive, the case was confirmed. Viremia was derived from the Ct value obtained for each sample tested.

The team found the CFR for patients with low, intermediate, and high viremia was 21%, 53%, and 81%, respectively. Compared to adults age 15 to 44 years, children under 5 years old and adults 45 and over had higher CFR, but children aged 5 to 14 had a lower CFR. They also noted that when the average viremia increased tenfold in July 2014, CFR increased as well, by 14%. The authors caution that these findings may not translate to cases outside the hospital setting. By knowing the relationship between viremia and CFR, doctors will be able to more accurately assess the efficacy of treatments for EVD in nonrandomized trials, and by stratifying participants by viremia group the investigators estimate other scientists will be able to reduce the sample size needed for randomized trials by 25%.

The authors concluded that in a very large and consecutive sample of patients with confirmed EVD, they have shown that viremia is a strong predictor of death that may in part explain previously observed heterogeneity in CFR estimates. Viremia may also provide an important mechanism for risk adjustment among patients in studies aiming to estimate associations of treatment with outcome, and a mechanism to stratify patients into different risk groups within clinical trials. The study was published on December 1, 2015, in the journal Public Library of Science Medicine.

Related Links:

Institut Pasteur 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Portable POCT Blood Gas Analyzer
BD100
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.